SWOG S1800E
A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or Without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-Based Chemotherapy and Immunotherapy for Stage
The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.
Navigation
About Us
Contact Us
- 2132 Broadwater Ave
- Suite A1
- Billings, MT 59102
- mccinfo@mtcancer.org
- (406) 969-6060
- (406) 969-6070
Copyright © Montana Cancer Consortium | All rights reserved